{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Survival and complete resolution of all signs of leukemia for 2 years after transplant with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakarypoiesis, more than 15% erythropoiesis and more than 25% granulocytopoiesis.\n2. Normalization of blood counts (no blasts, platelets \\>100,000/mm3, granulocytes \\>1,500/mm3).\n3. No extramedullary disease.","groups":[{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Dose Level 1: 12 Gy Iodine-131+ BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studie","id":"OG001","title":"Dose Level 7: 22 Gy Iodine-131+ BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studie","id":"OG002","title":"Dose Level 8: 24 Gy Iodine-131+ BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studie","id":"OG003","title":"Dose Level 9: 26 Gy Iodine-131+ BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studie","id":"OG004","title":"Dose Level 10: 28 Gy Iodine-131+ BC8"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who are alive and disease-free 2 years after transplant","reportingStatus":"POSTED","timeFrame":"2 years post transplant","title":"Two-year Disease-free Survival of Study Participants Who Completed the Study Regimen","type":"SECONDARY","unitOfMeasure":"Participants"}